CA
DNA icon

Cliff Asness’s Ginkgo Bioworks DNA Stock Holding History

Cliff Asness’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.16M Buy
621,625
+326,837
+111% +$2.73M ﹤0.01% 1871
2026
Q1 		$1.81M Buy
294,788
+124,233
+73% +$1.03M ﹤0.01% 2421
2025
Q4 		$1.42M Buy
170,555
+19,860
+13% +$214K ﹤0.01% 2350
2025
Q3 		$2.2M Sell
150,695
-13,095
-8% -$157K ﹤0.01% 1923
2025
Q2 		$1.84M Buy
163,790
+4,851
+3% +$37.6K ﹤0.01% 1825
2025
Q1 		$906K Buy
158,939
+121,326
+323% +$1.24M ﹤0.01% 2088
2024
Q4 		$369K Sell
37,613
-2,818
-7% -$24.2K ﹤0.01% 2400
2024
Q3 		$330K Sell
40,431
-218,647
-84% -$2.19M ﹤0.01% 2357
2024
Q2 		$3.39M Buy
+259,078
New +$7.73M 0.01% 1212
2024
Q1 		– Sell
-980
Closed -$66.3K – 2436
2023
Q4 		$66.3K Buy
980
+393
+67% +$24.1K ﹤0.01% 2296
2023
Q3 		$42.4K Buy
+587
New +$46.9K ﹤0.01% 2291
2022
Q4 		– Sell
-15,310
Closed -$1.91M – 2216
2022
Q3 		$1.91M Buy
+15,310
New +$1.82M ﹤0.01% 1222

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Cliff Asness's DNA Position: Q2 2026 in Review

Cliff Asness increased its Ginkgo Bioworks (DNA) stake by 111% in Q2 2026, buying an estimated $2.73M and bringing the position to 621,625 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Cliff Asness first reported a position in DNA in Q3 2022 and has held it in 12 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Cliff Asness held 621,625 shares of Ginkgo Bioworks worth $6.16M as of Q2 2026.
  • Cliff Asness bought 326,837 Ginkgo Bioworks shares in Q2 2026, an estimated $2.73M.
  • Ginkgo Bioworks made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1871 holding.
  • Cliff Asness first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 12 quarters since.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.